Biosimulation Market by Product, Application & by End Users - Global Forecast to 2020

The global biosimulation market is expected to reach USD 2,107.99 million by 2020 from USD 1,034.93 million in 2015, at a CAGR of 15.29% between 2015 and 2020. By product, the market includes software and services. Based on application, the market is segmented into drug discovery, drug development, and others (defense, industrial bioprocessing, nutraceuticals, and agri-food production). The drug development application segment is further classified into preclinical testing and clinical trials. Preclinical testing includes ADME/Tox and PK/PD applications. The drug discovery segment is divided into target identification & validation and lead identification & optimization. The drug development segment will hold the largest share of the biosimulation market in 2015. The other applications segment is expected to grow at the highest rate.

The geographic segments included in this report are North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share in the global biosimulation market in 2015. Europe is expected to register the fastest growth.

Market growth is majorly driven by the availability of R&D investments in biotechnology and pharmaceutical industries. Other growth factors include the need to curtail drug discovery & development costs, technological advancements, growth in the biologics and biosimilars markets, and the increased use of personalized medicines.

A combination of bottom-up and top-down approaches was used to calculate the market sizes and growth rates of the global biosimulation market and its subsegments. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates. The report provides qualitative insights about growth rates, and market drivers for all subsegments. It maps market sizes and growth rates for each subsegment and identifies segments poised for rapid growth in each geographic segment. The report also includes company profiles of market leaders.

Reasons to Buy the Report:
The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.

The report provides insights on the following:
‧ Product Development: Product portfolios of the top players in the biosimulation market.
‧ Competitive Assessment: In-depth assessment of the business segments and product portfolios of the leading players in the biosimulation market.
‧ Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various biosimulation products and services across geographies.

TABLE OF CONTENTS

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.2.1 MARKETS COVERED 16
1.2.2 YEARS CONSIDERED FOR THE STUDY 16
1.3 CURRENCY 17
1.4 STAKEHOLDERS 17
2 RESEARCH METHODOLOGY 18
2.1 MARKET SIZE ESTIMATION 19
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 22
2.3 MARKET SHARE ESTIMATION 23
2.3.1 KEY DATA FROM SECONDARY SOURCES 23
2.3.2 KEY DATA FROM PRIMARY SOURCES 23
2.3.3 ASSUMPTIONS FOR THE STUDY 24
3 EXECUTIVE SUMMARY 25
4 PREMIUM INSIGHTS 29
4.1 LUCRATIVE OPPORTUNITIES IN THE GLOBAL BIOSIMULATION MARKET 29
4.2 LIFE CYCLE ANALYSIS, BY REGION (2015–2020) 30
5 MARKET OVERVIEW 32
5.1 INTRODUCTION 33
5.2 MARKET SEGMENTATION 33
5.2.1 BY PRODUCT 33
5.2.2 BY APPLICATION 34
5.2.3 BY END USER 34
5.3 MARKET DYNAMICS 35
5.3.1 DRIVERS 36
5.3.1.1 Growth in the pharmaceutical and biotechnology industries 36
5.3.1.2 Increase in R&D investments in the pharmaceutical and biotechnology industries 36
5.3.1.3 Technological advancements 37
5.3.1.4 Need to curtail drug discovery and development costs 37
5.3.1.5 Growth in the biologics and biosimilars market and increased use of personalized medicines 37
5.3.2 RESTRAINTS 39
5.3.2.1 Lack of standardization 39
5.3.2.2 Lack of trained professionals 39
5.3.3 OPPORTUNITIES 40
5.3.3.1 Emerging applications 40
5.3.4 CHALLENGES 41
5.3.4.1 Limited knowledge of biological systems and processes 41
5.3.5 TRENDS 42
5.3.5.1 Collaborations of universities and research labs with suppliers 42
6 BIOSIMULATION MARKET, BY PRODUCT 43
6.1 INTRODUCTION 44
6.2 SOFTWARE 46
6.2.1 PK/PD MODELING AND SIMULATION SOFTWARE 48
6.2.2 MOLECULAR MODELING AND SIMULATION SOFTWARE 49
6.2.3 PBPK MODELING AND SIMULATION SOFTWARE 50
6.2.4 TOXICITY PREDICTION SOFTWARE 50
6.2.5 TRIAL DESIGN SOFTWARE 51
6.2.6 OTHER SOFTWARE 52
6.3 SERVICES 53
6.3.1 IN-HOUSE SERVICES 55
6.3.2 EXTERNAL/CONTRACT SERVICES 55
7 BIOSIMULATION MARKET, BY APPLICATION 57
7.1 INTRODUCTION 58
7.2 DRUG DEVELOPMENT 59
7.2.1 PRECLINICAL TESTING 62
7.2.1.1 PK/PD 64
7.2.1.2 ADME/Tox 65
7.2.2 CLINICAL TRIALS 66
7.3 DRUG DISCOVERY 66
7.3.1 TARGET IDENTIFICATION AND VALIDATION 69
7.3.2 LEAD IDENTIFICATION AND OPTIMIZATION 70
7.4 OTHER APPLICATIONS 71
8 BIOSIMULATION MARKET, BY END USER 73
8.1 INTRODUCTION 74
8.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 76
8.3 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES 78
8.4 CONTRACT RESEARCH ORGANIZATIONS 80
8.5 REGULATORY AUTHORITIES 81
8.6 OTHER END USERS 83
?
9 GLOBAL BIOSIMULATION MARKET, BY REGION 85
9.1 INTRODUCTION 86
9.2 NORTH AMERICA 88
9.3 EUROPE 95
9.4 ASIA 101
9.5 REST OF THE WORLD (ROW) 107
10 COMPETITIVE LANDSCAPE 113
10.1 INTRODUCTION 113
10.2 STRATEGIC OVERVIEW 113
10.3 LEADING PLAYERS IN THE BIOSIMULATION MARKET 114
10.4 COMPETITIVE SITUATION AND TRENDS 115
10.4.1 PRODUCT UPGRADATION 115
10.4.2 AGREEMENTS, COLLABORATIONS, EXPANSIONS, AND PARTNERSHIPS 116
10.4.3 NEW PRODUCT AND SERVICE LAUNCHES 117
10.4.4 ACQUISITIONS 118
10.4.5 OTHER DEVELOPMENTS 118
11 COMPANY PROFILES 120
11.1 INTRODUCTION 120
11.2 CERTARA USA, INC. 121
11.3 SIMULATION PLUS INC. 123
11.4 DASSAULT SYSTEMES SA 125
11.5 SCHRODINGER INC. 127
11.6 ADVANCED CHEMISTRY DEVELOPMENT, INC. 129
11.7 CHEMICAL COMPUTING GROUP, INC. 131
11.8 ENTELOS HOLDING CORPORATION 132
11.9 GENEDATA AG 133
11.10 PHYSIOMICS PLC 134
11.11 RHENOVIA PHARMA LTD. 136
*Details On Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured In Case Of Unlisted Companies.
12 APPENDIX 137
12.1 INSIGHTS OF INDUSTRY EXPERTS 137
12.2 DISCUSSION GUIDE 138
12.3 OTHER DEVELOPMENTS 141
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 146
12.5 AVAILABLE CUSTOMIZATIONS 147
12.6 RELATED REPORTS 148